Abstract Details

Title A Case-Control Study To Investigate the Association between Yerba Mate (Ilex paraguaiensis) Consumption and Risk of Parkinson's Disease. Preliminary Data

Topic Movement Disorders

Presentation(s) P03 - (-)

Poster/Presentation
Number 064

Objective

Background BACKGROUND: Mate is a very common beverage in some countries of South America. Yerba Mate (YM) comes from the dried leaves of the small tree (Ilex paraguaiensis). This drink is called "Mate" and has xanthynes between its components. Experimental studies suggests that YM could have a neuro protective rol in development and progression of Parkinson disease (PD) probably related to the adenosine A2A receptor antagonism or an augmentation of the expression in the striatum of adenosine A1 receptor mediated by xanthynes.

Design/Methods DESIGN/METHODS: Case-control study on an individual basis from hospital records. Case was defined as a 40 years or older PD individual with ? 4 years of disease duration. Other causes of Parkinsonism were excluded. Samples were matched by sex and age (± 2 years). Exposure was measure by YM consumption, coffee, tea, alcohol intake and smoking. Clinical and demographic data were recorded.

Results RESULTS: This preliminary analysis included 58 cases and 171 controls. Mean age of PD diagnosis 68.4 years, mean disease duration 7.16±4.81 years. There was an inverse association between YM consumption and PD (p=0.05). Multivariate analysis with logistic regression adjusted by sex, alcohol intake and smoking showed for YM OR: 0.75(IC95%:0.57-1.00), Tea OR: 0.54, (IC95%:0.30-0.97), Coffee OR: 0.55, (IC95%:0.28-1.07). All infusions considered together had OR: 0.69, (IC95%:0.53-0.89).

Conclusions CONCLUSIONS: We found an inverse association between intake of YM and PD, and a potential inverse association is suggested between YM and risk of PD. These results leads us to hypothesize that YM may have a potential protecting role in developing PD. Further studies in this direction should be conducted.

Authors/Disclosures
PRESENTER	No disclosure on file
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.
Carlos Melcon	No disclosure on file
	No disclosure on file
Tomoko Arakaki	No disclosure on file
	No disclosure on file
Jose A. Bueri, MD	No disclosure on file
Hernan Pavon, PhD (Biogen Idec)	No disclosure on file
Emilia M. Gatto, MD, FAAN (INEBA)	Dr. Gatto has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Gatto has received personal compensation in the range of $0-$499 for serving as a Consultant for Bago Argentina. Dr. Gatto has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bago. Dr. Gatto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Gatto has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Janssen. Dr. Gatto has received research support from Roche. The institution of Dr. Gatto has received research support from CHDI.

��ɫ��

��ɫ��